Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Soluble Erythropoietin Receptor Contributes to Erythropoietin Resistance in End-Stage Renal Disease

BACKGROUND Erythropoietin is a growth factor commonly used to manage anemia in patients with chronic kidney disease. A significant clinical challenge is relative resistance to erythropoietin, which leads to use of successively higher erythropoietin doses, failure to achieve target hemoglobin levels, and increased risk of adverse outcomes. Erythropoietin acts through the erythropoietin receptor ...

متن کامل

Soluble Adiponectin is a New Predictor for Cardiovascular Complications in Patients with End Stage Renal Disease

Mortality due to cardiovascular complications (CVC) in patients with end stage renal disease (ESRD) is 20 fold higher than in general population. Adiponectin (ADPN) hormone from adipose tissues accumulation in serum is attributed to reduced renal clearance. The aim of this study was to investigate the possible role of ADPN as a predictor of CVC in adult patients with ESRD on hemodialysis (HD), ...

متن کامل

Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatment

1. van Hensbroek MB, Onyiorah E, Jaffar S et al. A trial of artemether or quinine in childrenwith cerebralmalaria.NEngl JMed1996; 335: 69–75 2. Hien TT, Day NPJ, Phu NH et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76–83 3. Karunajeewa HA, Mueller I, Senn M et al. A trial of combination antimalarial therapies in c...

متن کامل

Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.

OBJECTIVE To assess the cost benefits of low dose subcutaneous recombinant human erythropoietin in correcting the anaemia of end stage renal disease. DESIGN Three year retrospective study. SETTING Subregional nephrology service serving a mixed urban and rural population of 800,000. SUBJECTS 60 patients with symptoms of anaemic end stage renal disease treated with erythropoietin (43 receiv...

متن کامل

Effect of Periodic Transfusion on Erythropoietin Concentration in End Stage Renal Disease

BACKGROUND It has been reported that a feedback circuit exists between erythropoietin (EPO) concentration and the degree of anemia even in end stage renal disease (ESRD), and growing experience with subcutaneous EPO administration confirms that only slight increases in EPO levels are required to correct renal anemia. Keeping in mind these findings, if a small portion of reserved EPO production ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: PLoS ONE

سال: 2010

ISSN: 1932-6203

DOI: 10.1371/journal.pone.0009246